⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ROIV News
Roivant Sciences Ltd. Common Shares
Form 8-K
sec.gov
ROIV
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
globenewswire.com
ROIV
ROIVW
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
globenewswire.com
ROIV
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
globenewswire.com
ROIV
IMVT
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
globenewswire.com
ROIV
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
globenewswire.com
IMVT
ROIV
Form 8-K
sec.gov
ROIV
Form 8-K
sec.gov
ROIV
Dr. Gillian Cannon Joins Lindus Therapeutics’ Board as a Non-Executive Director
globenewswire.com
ROIV
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
globenewswire.com
ROIV